| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
NDSB-195 acts as a protein solubilizing and stabilizing agent. It prevents protein aggregation during purification or refolding without disrupting native protein structure. The compound enhances the dynamics of the β4-α2 loop of ubiquitin. It stabilizes Saccharomyces cerevisiae ubiquitin against guanidinium chloride denaturation, increasing the onset temperature of heat denaturation in the presence of the denaturant. The compound's mechanism involves modifying proteins through stabilization of protein complexes and identification of interacting partners. It also acts as a protein stabilizer in various applications.
|
|---|---|
| ln Vitro |
In vitro, NDSB-195 is used for protein purification and refolding. It prevents protein aggregation and facilitates proper folding without increasing solution viscosity, outperforming classical osmolytes. The compound is useful for nuclear protein recovery, precipitation reduction in isoelectric focusing, and membrane-bound protease purification. It enhances the dynamics of the β4-α2 loop of ubiquitin and stabilizes ubiquitin against denaturation. The compound is zwitterionic over a wide pH range and has no significant UV absorption.
|
| ln Vivo |
In vivo data for NDSB-195 is limited, as it is primarily a research reagent for protein biochemistry. The compound is classified for research use only and is not intended for human or veterinary applications. Its primary applications are in protein purification, stabilization, and crystallization. The compound's ability to stabilize proteins against denaturation suggests potential for in vivo applications in protein therapeutics, though specific data is not available. The compound is not a therapeutic agent.
|
| Enzyme Assay |
In vitro protein stabilization assays for NDSB-195 typically evaluate its ability to prevent protein aggregation and stabilize protein structure. A standard assay protocol involves incubating a model protein (e.g., ubiquitin) with varying concentrations of NDSB-195 (typically 0.1-1 M) in appropriate buffer systems. Protein aggregation is monitored by light scattering or size exclusion chromatography. Protein stability is assessed by measuring thermal denaturation temperature (Tm) using circular dichroism or differential scanning calorimetry. The compound's ability to enhance protein dynamics can be evaluated by NMR or hydrogen-deuterium exchange mass spectrometry.
|
| Cell Assay |
Cellular assays for NDSB-195 are not typically performed, as it is primarily a protein biochemistry reagent rather than a cell-modulating agent. The compound is used in cell lysis and protein extraction buffers to stabilize proteins during purification. A typical protocol involves adding NDSB-195 to lysis buffers at concentrations of 0.5-1 M. Cells are lysed and proteins are extracted. Protein yield and activity are compared with and without NDSB-195. The compound's ability to prevent protein aggregation during cell lysis is evaluated.
|
| Animal Protocol |
In vivo animal studies for NDSB-195 are not standard, as it is primarily a protein biochemistry reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to evaluating the compound as a formulation excipient for protein therapeutics. The compound's primary value lies in its use for protein purification and stabilization in research settings. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NDSB-195 is not applicable, as it is a protein biochemistry reagent rather than a pharmaceutical agent. The compound has a molecular weight of 195.28 g/mol and a molecular formula of C₇H₁₇NO₃S. It is stored as a solid at room temperature. The compound is zwitterionic over a wide pH range and is easily removed by dialysis. It has no significant absorption in the near UV range. The compound is classified as a dangerous goods item for transport.
|
| Toxicity/Toxicokinetics |
Toxicological data for NDSB-195 is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
NDSB-195 (Dimethylethylammoniumpropane sulfonate, CAS 160255-06-1) is a non-detergent sulfobetaine used for protein solubilization and stabilization. It prevents protein aggregation during purification or refolding. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to protein biochemistry research.
|
| Molecular Formula |
C7H17NO3S
|
|---|---|
| Molecular Weight |
195.28
|
| Exact Mass |
195.093
|
| CAS # |
160255-06-1
|
| PubChem CID |
5221296
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>300ºC
|
| LogP |
1.098
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
12
|
| Complexity |
202
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC[N+](C)(C)CCCS([O-])(=O)=O
|
| InChi Key |
NNCRHRDBFDCWPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H17NO3S/c1-4-8(2,3)6-5-7-12(9,10)11/h4-7H2,1-3H3
|
| Chemical Name |
3-[ethyl(dimethyl)azaniumyl]propane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 125 mg/mL (640.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1209 mL | 25.6043 mL | 51.2085 mL | |
| 5 mM | 1.0242 mL | 5.1209 mL | 10.2417 mL | |
| 10 mM | 0.5121 mL | 2.5604 mL | 5.1209 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
